OS Therapies Initiates FDA BLA Filing for OST-HER2 to Prevent or Delay Recurrent Pulmonary Metastatic Osteosarcoma
Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data OS Therapies Inc. (NYSE:OSTX) NEW YORK, NY, UNITED STATES, February 2, 2026 /EINPresswire.com/ -- OS Therapies Inc. (NYSE …